FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W66155076> ?p ?o ?g. }

• W66155076 endingPage "558" @default.
• W66155076 startingPage "553" @default.
• W66155076 abstract "BACKGROUND: Methotrexate (MTX) is effective in remission induction and maintenance in steroid-dependent Crohn's disease (CD), but is often considered to be a second-line immunosuppressive agent, to be used in cases of failure or intolerance to azathioprine (AZA) or 6-mercaptopurine (6-MP). This may be related to concerns about hepatotoxicity, but this adverse effect is rare in monitored CD patients taking MTX. Still, there are no guidelines for monitoring patients with CD on MTX, and physicians must decide based on rheumatological literature about how to monitor their patients. PURPOSE: To determine the patterns of MTX use in patients with CD by Canadian gastroenterologists, examining the reasons for choosing MTX versus AZA/6-MP, the doses and routes of administration of MTX, and how patients on MTX are monitored, including the use of liver biopsy. METHODS: A self-report survey was sent to physician members of the Canadian Association of Gastroenterology, with a second mailing three months later to increase response rate. RESULTS: Of 490 surveys mailed, a 54.9% response rate was achieved. Of adult gastroenterologists, 60.7% stated they never use MTX as a first-line immunosuppressive agent, and 33.3% never use MTX at all. The most common reasons for choosing MTX were a contraindication to the use of AZA/6-MP (43.7%) and patient preference (22.5%). MTX is used intramuscularly in 41.5%, subcutaneously in 31.8%, and orally in 26.7% of patients. The most common dose used for remission induction was 25 mg/week (84.2%; range 7.5 mg/week to 50 mg/week; three responders used more frequent dosing than weekly) and for remission maintenance was 15 mg/week (55.4%; range 7.5 mg/week to 50 mg/week; three responders used more frequent dosing than weekly). Most responders checked a liver profile and complete blood count at baseline and serially. Of those who used MTX, 26.5% routinely performed liver biopsy after an accumulated dose of MTX had been taken (usually 1 g to 2 g), 57.7% sometimes performed liver biopsy, and 16.8% never performed liver biopsy. Of pediatric gastroenterologists, 17.6% never used MTX, but those who used it prescribed it subcutaneously (80.0%) more often than intramuscularly (17.5%) or orally (2.5%). CONCLUSIONS: MTX was used as a first-line immunosuppressive agent in patients with CD by a minority of Canadian gastroenterologists. When used, there is variability in how MTX is prescribed and monitored. Although hepatotoxicity is rare, liver biopsy was performed frequently and probably often unnecessarily." @default.
• W66155076 created "2016-06-24" @default.
• W66155076 creator A5058366322 @default.
• W66155076 creator A5065846093 @default.
• W66155076 creator A5070640488 @default.
• W66155076 date "2005-01-01" @default.
• W66155076 modified "2023-10-16" @default.
• W66155076 title "A Survey of Canadian Gastroenterologists about the Use of Methotrexate in Patients with Crohn’s Disease" @default.
• W66155076 cites W109571900 @default.
• W66155076 cites W117175198 @default.
• W66155076 cites W129429327 @default.
• W66155076 cites W1522944862 @default.
• W66155076 cites W1761355724 @default.
• W66155076 cites W1937198559 @default.
• W66155076 cites W1976676963 @default.
• W66155076 cites W1977223866 @default.
• W66155076 cites W1984190326 @default.
• W66155076 cites W2000127649 @default.
• W66155076 cites W2001199131 @default.
• W66155076 cites W2006201672 @default.
• W66155076 cites W2009285886 @default.
• W66155076 cites W2009614949 @default.
• W66155076 cites W2024293518 @default.
• W66155076 cites W2025343624 @default.
• W66155076 cites W2037707239 @default.
• W66155076 cites W2041654104 @default.
• W66155076 cites W2042452027 @default.
• W66155076 cites W2043258441 @default.
• W66155076 cites W2046673451 @default.
• W66155076 cites W2046974694 @default.
• W66155076 cites W2055280685 @default.
• W66155076 cites W2059884846 @default.
• W66155076 cites W2068553412 @default.
• W66155076 cites W2069009549 @default.
• W66155076 cites W2072179061 @default.
• W66155076 cites W2086848741 @default.
• W66155076 cites W2089392787 @default.
• W66155076 cites W2092985266 @default.
• W66155076 cites W2098638622 @default.
• W66155076 cites W2109713854 @default.
• W66155076 cites W2130843450 @default.
• W66155076 cites W2132517981 @default.
• W66155076 cites W2154117979 @default.
• W66155076 cites W2314055620 @default.
• W66155076 cites W2326745462 @default.
• W66155076 cites W3144276899 @default.
• W66155076 doi "https://doi.org/10.1155/2005/382379" @default.
• W66155076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16151547" @default.
• W66155076 hasPublicationYear "2005" @default.
• W66155076 type Work @default.
• W66155076 sameAs 66155076 @default.
• W66155076 citedByCount "14" @default.
• W66155076 countsByYear W661550762012 @default.
• W66155076 countsByYear W661550762013 @default.
• W66155076 countsByYear W661550762022 @default.
• W66155076 crossrefType "journal-article" @default.
• W66155076 hasAuthorship W66155076A5058366322 @default.
• W66155076 hasAuthorship W66155076A5065846093 @default.
• W66155076 hasAuthorship W66155076A5070640488 @default.
• W66155076 hasBestOaLocation W661550761 @default.
• W66155076 hasConcept C126322002 @default.
• W66155076 hasConcept C141071460 @default.
• W66155076 hasConcept C142724271 @default.
• W66155076 hasConcept C197934379 @default.
• W66155076 hasConcept C204787440 @default.
• W66155076 hasConcept C2776494729 @default.
• W66155076 hasConcept C2776760755 @default.
• W66155076 hasConcept C2777173762 @default.
• W66155076 hasConcept C2779134260 @default.
• W66155076 hasConcept C2779280984 @default.
• W66155076 hasConcept C2781059491 @default.
• W66155076 hasConcept C71924100 @default.
• W66155076 hasConcept C90924648 @default.
• W66155076 hasConceptScore W66155076C126322002 @default.
• W66155076 hasConceptScore W66155076C141071460 @default.
• W66155076 hasConceptScore W66155076C142724271 @default.
• W66155076 hasConceptScore W66155076C197934379 @default.
• W66155076 hasConceptScore W66155076C204787440 @default.
• W66155076 hasConceptScore W66155076C2776494729 @default.
• W66155076 hasConceptScore W66155076C2776760755 @default.
• W66155076 hasConceptScore W66155076C2777173762 @default.
• W66155076 hasConceptScore W66155076C2779134260 @default.
• W66155076 hasConceptScore W66155076C2779280984 @default.
• W66155076 hasConceptScore W66155076C2781059491 @default.
• W66155076 hasConceptScore W66155076C71924100 @default.
• W66155076 hasConceptScore W66155076C90924648 @default.
• W66155076 hasIssue "9" @default.
• W66155076 hasLocation W661550761 @default.
• W66155076 hasLocation W661550762 @default.
• W66155076 hasLocation W661550763 @default.
• W66155076 hasOpenAccess W66155076 @default.
• W66155076 hasPrimaryLocation W661550761 @default.
• W66155076 hasRelatedWork W1986095852 @default.
• W66155076 hasRelatedWork W2009285886 @default.
• W66155076 hasRelatedWork W2028579708 @default.
• W66155076 hasRelatedWork W2067163776 @default.
• W66155076 hasRelatedWork W2102662634 @default.
• W66155076 hasRelatedWork W2162268056 @default.

• next